['chronic lymphocytic leukemia']
['ublituximab', 'ibrutinib']

        Inclusion Criteria:

          -  Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment

          -  At least one high-risk cytogenetic feature defined by the presence of 17p deletion,
             11q deletion and/or p53 mutation

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

        Exclusion Criteria:

          -  Any major surgery, chemotherapy or immunotherapy within the last 21 days

          -  Evidence of hepatitis B virus, hepatitis C virus or known HIV infection

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Prior
             Allogeneic hematologic stem cell transplant is excluded

          -  Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's
             transformation)

          -  Previous therapy with ibrutinib, or any drug that specifically inhibits Bruton's
             tyrosine kinase (BTK)
      